Phase I Study of BVD-523 in Patients with Advanced Malignancies

Diseases and Conditions Researched

Melanoma, skin

What is the purpose of this trial?

To define the safety and tolerability of BVD-523 in patients with advanced malignancies by determining the dose-limiting toxicities (DLT), the maximum tolerated dose (MTD), and the recommended Phase 2 Dose (RP2D).

Participation Guidelines

Age: 18 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: BioMed Valley Discoveries, Inc.
Last Updated:
Study HIC#: 1303011687